Metsera (MTSR) & Its Peers Critical Review

Metsera (NASDAQ:MTSR) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare Metsera to similar companies based on the strength of its valuation, earnings, analyst recommendations, profitability, risk, institutional ownership and dividends.

Insider & Institutional Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Metsera and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metsera	N/A	-$209.13 million	-11.16
Metsera Competitors	$951.13 million	-$44.98 million	12.83

Metsera’s competitors have higher revenue and earnings than Metsera. Metsera is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Metsera and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metsera	N/A	-121.12%	-53.54%
Metsera Competitors	-1,425.99%	-589.65%	-28.81%

Analyst Recommendations

This is a summary of recent ratings for Metsera and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metsera	1	3	4	0	2.38
Metsera Competitors	5916	12229	37690	1173	2.60

Metsera currently has a consensus target price of $55.75, suggesting a potential downside of 20.92%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.10%. Given Metsera’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Metsera has less favorable growth aspects than its competitors.

Summary

Metsera competitors beat Metsera on 10 of the 12 factors compared.

Metsera Company Profile

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.